undamentalytics Newsletter

Shah Rajeev M.: insider trades

Director, 10% owner at 14 companies we cover. 14 open-market purchases and 9 sales not made under a pre-set plan, reported from October 5, 2018 to August 14, 2026.

Would copying Shah Rajeev M.’s purchases have beaten the S&P 500?

Too few purchases to judge. Only 10 purchases have 12 months of prices after the report; we judge insiders once they have 20. The figures below can swing a long way on a handful of trades. Buying each purchase the day after it was reported, an equal amount each, and holding it 12 months or until they reported a sale would have turned $10,000 on October 8, 2018 into $1,384 by November 2, 2026, −21.8% a year. The copy held shares only 55% of the time, so the fair comparison is the S&P 500 on those same days with Treasury bills otherwise: $25,562, +12.4% a year (the S&P 500 held throughout made $29,626, +14.5% a year). Beta against the index was 0.60. Twelve months after each report, the average purchase was −36.4% against the S&P 500 (median −35.4%), and 0% beat it. Measured from the trade date, the insider’s own timing, the average was −33.8%. After their sales, the shares moved −64.0% against the index over 12 months on average (a negative figure means selling was the right call); 100% trailed it.

With 296 insiders tested, some will look skilled or unskilled by chance alone: when we replaced each insider’s stocks with random companies bought on the same days, about 5.7 cleared the bar ahead and 23.3 behind. One record on its own proves little.

$0$10.0k$20.0k$30.0k 201820192020202120222023202420252026 $29.6k$25.6k$1.4k
Copying Shah Rajeev M.S&P 500, same days investedS&P 500, held throughout $10,000 copying Shah Rajeev M.’s open-market purchases from October 8, 2018, before costs and taxes, marked weekly. Each purchase gets the same starting stake, bought at the close of the first trading day after the report and sold 12 months later or the day after a reported sale of that stock; uninvested money earns the Treasury bill rate. “Same days invested” holds the S&P 500 only on the days the copy held shares, Treasury bills otherwise.
Return a year, copying
−21.8%
S&P 500, same days invested
+12.4% (held throughout +14.5%)
Time in shares
55%
Sharpe ratio (S&P 500)
−0.35 (0.65)
Biggest drop (S&P 500)
−88% (−34%)
Market sensitivity (beta)
0.60
Purchases copied
12

Trade by trade

Shah Rajeev M.: trades against the S&P 500 afterwards
MeasuredTrades countedAverage vs S&P 500MedianWent the right wayYearst-statisticp-valueEvidence
Purchases, 3 months after the report 12 +0.7% −10.4% 25% 4 0.41 0.71 No reliable evidence
Purchases, 6 months after the report 11 +0.3% −1.5% 46% 4 −1.38 0.26 No reliable evidence
Purchases, 12 months after the report 10 −36.4% −35.4% 0% 3 — — Not enough years
Purchases, 12 months after the trade 10 −33.8% −27.9% 0% 3 — — Not enough years
Sales, 3 months after the report 6 −19.2% −24.7% 67% 3 — — Not enough years
Sales, 12 months after the report 4 −64.0% −63.0% 100% 2 — — Not enough years
Sales, 12 months after the trade 4 −69.4% −69.4% 100% 2 — — Not enough years

“Average vs S&P 500” is the stock’s return including dividends minus the index’s over the same dates, from the close on the first trading day after the report, or from the close on the trade date. Only windows that have finished are counted. For sales, a negative figure means the stock lagged after it was sold, so selling was the right call (green). “Went the right way” is the share of purchases that beat the index, or of sales that trailed it. The t-statistic uses one average per year of reports, because one person’s trades bunch into the same stock and weeks, and needs trades in at least four different years; the p-value comes from the t distribution with that number of years (with four years, a t of 2 has p = 0.14). “Some evidence” means p under 5%, “strong evidence” p under 1% over at least six years.

Companies traded

CompanyTitle on the latest filingPurchasesSalesFirst reportLatest report
Cytek Biosciences, Inc. CTKB —40February 22, 2022March 11, 2022
Kala BIO, Inc. KALA —21October 5, 2018May 25, 2022
Vor Biopharma Inc. VOR —03October 17, 2025April 24, 2026
Vaxcyte, Inc. PCVX —02October 1, 2020October 9, 2020
Enliven Therapeutics, Inc. ELVN —20October 24, 2022December 12, 2022
Verastem, Inc. VSTM —01April 29, 2020April 29, 2020
Rhythm Pharmaceuticals, Inc. RYTM —01June 29, 2020June 29, 2020
Nkarta, Inc. NKTX —10April 28, 2022April 28, 2022
An2 Therapeutics, Inc. ANTX —10August 5, 2022August 5, 2022
Werewolf Therapeutics, Inc. HOWL —10January 10, 2023January 10, 2023
Jade Biosciences, Inc. JBIO —10June 20, 2024June 20, 2024
Mineralys Therapeutics, Inc. MLYS —10March 31, 2026March 31, 2026
Artiva Biotherapeutics, Inc. ARTV —10July 14, 2026July 14, 2026
Septerna, Inc. SEPN —01August 14, 2026August 14, 2026

Trades and what followed

Moves are against the S&P 500; green means the trade went the insider’s way.

ReportedTradedCompanyTradeValue3 months after report12 months after report12 months after trade
August 14, 2026August 12, 2026 SEPN Sale $63,452,500 not yetnot yetnot yet
July 14, 2026July 10, 2026 ARTV Purchase $194,040 −39.9%not yetnot yet
April 24, 2026April 22, 2026 VOR Sale $2,604,416 +37.8%not yetnot yet
April 10, 2026April 8, 2026 VOR Sale $10,233,811 +6.0%not yetnot yet
March 31, 2026March 27, 2026 MLYS Purchase $8,762,797 −9.1%not yetnot yet
October 17, 2025October 15, 2025 VOR Sale $13,707,361 −41.0%−52.0%−56.3%
June 20, 2024June 17, 2024 JBIO Purchase $1,549,944 not yetnot yetnot yet
January 10, 2023January 6, 2023 HOWL Purchase $4,095,130 not yetnot yetnot yet
December 12, 2022December 8, 2022 ELVN Purchase $115,595 +24.2%−52.5%−47.7%
October 24, 2022October 20, 2022 ELVN Purchase $336,812 −6.8%−39.3%−41.6%
August 5, 2022August 3, 2022 ANTX Purchase $14,330 +60.6%−31.6%−9.4%
May 25, 2022May 23, 2022 KALA Sale $1,488,844 not yetnot yetnot yet
April 28, 2022April 26, 2022 NKTX Purchase $33,000,000 −32.6%−74.2%−71.8%
March 11, 2022March 9, 2022 CTKB Purchase $8,159,420 −9.3%−15.2%−21.8%
March 8, 2022March 4, 2022 CTKB Purchase $8,247,616 −13.1%−21.8%−19.4%
March 2, 2022February 28, 2022 CTKB Purchase $5,722,877 −11.6%−18.6%−22.3%
February 22, 2022February 17, 2022 CTKB Purchase $7,696,868 −19.4%−10.4%−18.8%
October 9, 2020October 7, 2020 PCVX Sale $13,522,253 −53.7%−72.9%−80.8%
October 1, 2020September 29, 2020 PCVX Sale $11,246,313 −55.6%−78.0%−82.6%
June 29, 2020June 25, 2020 RYTM Sale $3,465,863 −8.4%−53.1%−58.0%
April 29, 2020April 27, 2020 VSTM Sale $3,006,003 not yetnot yetnot yet
March 13, 2020March 13, 2020 KALA Purchase $49,999,995 +82.6%−40.4%−33.6%
October 5, 2018October 3, 2018 KALA Purchase $19,999,996 −16.9%−60.3%−51.5%

Open-market purchases and sales of at least $10,000 in companies we cover, from SEC Form 4 filings; sales made under a pre-set Rule 10b5-1 plan are not shown. “Not yet” means the window has not finished or the share price was under $5 at entry. These are the shares’ moves after each trade: they say nothing about why Shah Rajeev M. traded and do not suggest the use of non-public information. How every insider compares · the insider trading backtest.